Researchers looked past statistics to see how new Alzheimer’s treatments impacted patients’ daily life. (Chinnapong/Shutterstock) In a nutshell New Alzheimer’s medications (lecanemab and donanemab) may extend independence in daily activities by approximately 10-13 months for patients